Business
Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development
MGX-001 demonstrated curative FVIII activity in non-human primates Pre-IND regulatory meeting expected in Q4 2025 with investigational new drug (IND) and clinical trial application (CTA) submissions expected in 4Q 2026 EMERYVILLE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today reported new dose range finding data from t
About this update from Metagenomi Therapeutics, Inc.
[{"type":"image","alt":"Metagenomi, Inc.","displaySize":"","headline":null,"caption":"Metagenomi, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":120,"url":"https://media.zenfs.com/en/globenewswire.com/f9f4f8ce15a62dc256eccc8b2b88fc5f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Ld3K1HIDljOFxzdNkgn1rg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f9f4f8ce15a62dc256eccc8b2b88fc5f","width":300,"height":120}},"lazy":false},{"type":"text","content":"MGX-001 demonstrated curative FVIII activity in non-human primates ","length":66,"tagName":"p"},{"type":"text","content":"Pre-IND regulatory meeting expected in Q4 2025 with investigational new drug (IND) and clinical trial application (CTA) submissions expected in 4Q 2026","length":151,"tagName":"p"},{"type":"text","content":"EMERYVILLE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today reported new dose range finding data from the Company’s MGX-001 hemophilia A program. The data demonstrated curative factor VIII (FVIII) activity in non-human primates (NHPs) and informs a clinical dose regimen strategy for a therapy with best-in-class treatment potential. Metagenomi intends to advance MGX-001 into clinical development.","length":576,"tagName":"p"},{"type":"text","content":"“We are highly encouraged by the dose range finding results observed in this study where we have seen clear dose-dependent activity across both the AAV and LNP components of MGX-001, resulting in therapeutically relevant FVIII activity in each animal treated in all but the lowest AAV dose,” said Jian Irish, Ph.D., M.B.A., President and CEO of Metagenomi. “In contrast to bispecific FVIII mimetics or rebalancing therapies, MGX-001 enables endogenous production of FVIII for hemostatic regulation and restores the body’s own ability to produce FVIII for a potentially lifelong cure. Our new data builds upon an earlier study demonstrating durable and stable FVIII activity in NHPs over an approximately 19-month study, giving us confidence that our novel approach has the potential to be a curative, one-and-done treatment for patients suffering from hemophilia A. We are leveraging t...